This episode discusses "Hypogammaglobulinemia in MS Patients on Anti-CD20 Therapy: When to Act." Dr. Williams identifies hypogammaglobulinemia — low IgG levels resulting from prolonged B-cell depletion — as one of the most clinically consequential long-term complications of anti-CD20 therapy, and asks the panel how they identify high-risk patients and manage this finding.
Williams explains that at-home, once-monthly ofatumumab is generally well received by patients with relapsing MS, offering convenience for those with active work and family lives while addressing concerns about injections and treatment scheduling.
Neurology News Network for the week ending July 4th, 2026. [WATCH TIME: 4 minutes]
Ugur T. Sener, MD, discusses exploratory seizure analyses from the INDIGO trial, highlighting reductions in seizure frequency with vorasidenib and the potential biologic relationship between tumor control and epileptogenesis.
In this episode titled "Managing Infection Risk and Safety Monitoring with Anti-CD20 MS Disease Modifying Therapy," Dr. Williams raises the issue of infection risk — a topic of increasing clinical relevance.
With the first anti-CD20 therapy approved for MS now more than ten years in clinical use, in this episode titled "Long-Term Efficacy of Anti-CD20 Therapies in MS: What the Evidence Shows," Dr. Williams asks Dr. Krieger what the long-term evidence reveals about efficacy — and whether there have been any surprises.
Following the FDA's expanded approval of efgartigimod, the neuromuscular physician at Erlanger Health Systems discusses the implications for seronegative disease, treatment sequencing, and the evolving definition of antibody-negative MG. [WATCH TIME: 5 minutes]
At ATMRD 2026, a neurologist at UCLA discussed the growing recognition of demoralization in Parkinson disease, highlighting how it differs from depression and apathy and outlining strategies to help patients maintain resilience, purpose, and quality of life. [Watch time: 5 minutes]
Williams outlines how active disease features, lifestyle needs, and prior experience with injectable therapies inform selection of ofatumumab as a high-efficacy, self-administered option for patients with relapsing multiple sclerosis.
Williams describes how the shift toward early use of high-efficacy therapy in relapsing MS has brought ofatumumab, an at-home, subcutaneous anti-CD20 agent, into treatment discussions at the start of the disease course.
The chief scientific officer of the Parkinson’s Foundation discussed how the PD Trial Navigator program helps to identify individuals with Parkinson Disease who may be eligible for the phase 2 NEULARK study. [WATCH TIME: 4 minutes]
The professor of neurology at UT Southwestern Medical Center discussed the Octave Multiple Sclerosis Disease Activity Test as a complementary tool to MRI and clinical assessment in MS. [WATCH TIME: 6 minutes]
The discussion turns to the pivotal INDIGO trial, with a focus on how vorasidenib improved progression-free survival and introduced a new early treatment strategy for patients with grade 2 IDH-mutant glioma following surgery
The associate professor at Johns Hopkins University discussed emerging biomarkers outside of neurofilament light chain, including muscle MRI, immune-targeted markers, and microRNA research in peripheral nerve disorders. [WATCH TIME: 3 minutes]
The associate clinical professor at the University of South Carolina School of Medicine discussed data presented at SLEEP 2026 from a phase 2 study of orexin 2 receptor agonist alixorexton in narcolepsy type 2. [WATCH TIME: 3 minutes]
In this episode, moderator Dr. Mitzi Joi Williams discusses Anti-CD20 Therapies in multiple sclerosis with Dr. Stephen Krieger, Dr. Benjamin Greenberg, and Dr. Riley Bove. Dr. Williams notes that while three anti-CD20 agents are FDA-approved for MS (ocrelizumab approved in 2017, followed by ofatumumab and ublituximab), rituximab has been used off-label for many years. Though these agents target the same molecule, they differ in meaningful ways.
In "Why Anti-CD20 Therapy Has Become a Cornerstone of MS Treatment" episode, panelists explore the anti-CD20 drug class itself — a group of B-cell depleting therapies that have become the most commonly initiated treatments for MS in the United States. Experts recount that the field initially viewed B-cell targeting as counterintuitive in what was long considered a T-cell-mediated disease. However, experience and trial data have demonstrated that depleting CD19/CD20-positive B cells produces profound downstream immunological effects that dramatically suppress MS disease activity.
Neurology News Network for the week ending June 20th, 2026. [WATCH TIME: 4 minutes]
Maya Hrachova, DO, neurologist and neuro-oncologist at Allina Health Brain and Spine Institute, discusses the evolving role of neurologic consultation in cancer care and the importance of accurate diagnosis in complex oncology patients.
In this episode, “Family Burden and Lifelong Care Planning in Dravet Syndrome,” the panelists explore the far-reaching impact of Dravet syndrome on caregivers, families, and support networks.
This episode, titled “Dravet Syndrome Disease Modification Beyond Seizure Control,” features panelists discussing the evolving role of disease-modifying therapies across the full spectrum of Dravet syndrome, including adolescents and adults.
In “Emerging Therapies in Dravet Syndrome,” our panel explores how investigational therapies may reshape the future treatment landscape for patients with Dravet syndrome.
In “Unmet Needs and the Impact of Disease Modifying Therapies in Dravet Syndrome,” the panelists explore the limitations of current treatment approaches and discusses how emerging disease-modifying therapies may transform the future management of Dravet syndrome. Expert faculty review the significant advances achieved with currently available antiseizure medications while acknowledging that substantial unmet needs remain for many patients and families.
This episode, titled “Dravet Syndrome Treatment Monitoring and Goals for Long-Term Management,” features panelists discussing the practical considerations that guide treatment selection and ongoing management for patients with Dravet syndrome.
In “Dravet Syndrome Managing Refractory Seizures Across the Lifespan,” our panel explores the ongoing challenges of treating refractory seizures in patients with Dravet syndrome despite significant advances in available therapies.
In this episode “Current Treatment Strategies for Dravet Syndrome,” the panelists explore how genetic findings influence treatment selection and long-term management in Dravet syndrome. Expert faculty discuss the practical realities of treating patients when clinical suspicion for Dravet syndrome exists before genetic confirmation is available, emphasizing the importance of initiating appropriate management early and avoiding therapies that may worsen outcomes.
In “Interpreting Variants of Uncertain Significance in Dravet Syndrome,” our panel explores one of the most challenging aspects of genetic testing: the interpretation and clinical management of variants of uncertain significance (VUS).
In “The Role of Genetic Counseling and Community Resources in Dravet Syndrome,” our panel explores the critical role genetic counselors play throughout the genetic testing process and the broader impact of establishing a molecular diagnosis for patients with Dravet syndrome and other genetic epilepsies
In this episode, “Navigating Unresolved Genetic Findings in Dravet Syndrome,” the panelists explore the challenges clinicians face when genetic testing fails to identify a clear cause of disease and discuss the importance of ongoing re-evaluation in patients with suspected genetic epilepsies.
This episode, titled “Genetic Testing Approaches in Dravet Syndrome,” features panelists discussing the rapidly evolving landscape of genetic testing and how clinicians can navigate the growing number of testing options available for patients with suspected Dravet syndrome.